Important note: Information in this article was accurate in June 2006. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - Vol. 7, No. 6, June 2006
Polly Clayden, HIV i-Base
Neonates receive antiretroviral prophylaxis often involving AZT either alone or in association with 3TC. Since access to intracellular NRTI triphosphate (TP) measurement is limited, pharmacological intracellular data are still lacking.
A poster from L. Durand-Gasselin and coworkers presented findings from a study to measure AZT and 3TC plasma levels, as well as intracellular phosphorylated metabolites concentrations, in HIV exposed babies born to HIV positive mothers.
52 HIV exposed neonates (age range: 0-45 days) received AZT (8 mg/kg/24h), either alone (n = 32) or with 3TC (4mg/kg/24h) (n = 20). Plasma and PBMCs were isolated from blood and intracellular NRTI metabolites (AZT-TP, d4T-TP, 3TC-TP) and plasma NRTI (AZT, d4T, 3TC) concentrations were determined using validated LC-MS/MS assays.
The investigators found plasma AZT and intracellular AZT-TP levels in the neonates decreased significantly with age (p<0.0001). The median AZT-TP concentration reached 202.2 fmol/106 cells (CV%=44) between days1 and 8, but only 62.9 fmol/106 cells (CV%=65) between days 32 and 40. They suggest that this phenomenon could be explained by the maturation of intestinal, hepatic and renal functions occurring during the first weeks of life.
Therefore, they observed high AZT and AZT-TP levels during the first week as compared to adult historical data. Intracellular levels of d4T-TP closely correlate with those of AZT-TP with an average d4T-TP to AZT-TP ratio of 0.28. Plasma 3TC and intracellular 3TC-TP levels did not differ significantly by age. The median 3TC-TP concentration was 19 pmol/106 cells, which is consistent with adult data.
They noted that babies receiving AZT monotherapy, whose mother’s treatment included 3TC, had residual plasma 3TC and intracellular 3TC-TP up to one week after birth. The investigators wrote: “We observed high concentration of AZT and related intracellular metabolites (AZT-TP and d4T-TP) during the first week of life. Following the first fortnight, intracellular NRTI-TP measurements showed no major difference with adults in term of 3TC-TP levels and metabolic pathway from AZT to d4T and d4T-TP.” They added: “These characteristics, in favor of efficacy, could have some drawbacks in terms of mitochondrial toxicity.”
Ref: Durand-Gasselin L, Pruvost A, Dehée A et al. Intracellular and plasma measurements of AZT and 3TC and their metabolites in newborn babies from HIV infected mothers. 7th International Workshop on Clinical Pharmacology of HIV Therapy, 20-22 April 2006, Lisbon. Abstract 25.
2006-06-10
IB060706-10
©2006. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.